A Randomized Phase II Study Of Concurrent Intensity Modulated Radiation Therapy (Imrt), Paclitaxel, And Pazopanib (Nsc 737754)/Placebo For The Treatme
Posted Date: May 15, 2019
- Investigator: Kevin Redmond
- Type of Study: Drug
The purpose of this study is to determine whether adding pazopanib to paclitaxel and radiation (chemoradiotherapy) is safe and tolerable. The study also will compare the effects, good and/or bad, of chemoradiotherapy and pazopanib with chemoradiotherapy and a placebo (inactive substance) on you and
Criteria:
To Qualify You Must Have Anaplastic Thyroid Cancer.
Keywords:
Anaplastic, Cancer, R0912, Thyroid Cancer
For More Information:
Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu